Abstract:Graphical and Lay Summary Recombinant adeno‐associated virus (rAAV) is a widely used gene delivery vehicle for human gene therapies, but large‐scale rAAV manufacturing using plasmid transfection and virus infection faces challenges such as cost and inefficiency. This study presents an innovative platform by enhancing previously developed synthetic rAAV producer cell lines. These high‐producing cell lines were integrated with all essential viral components and supplemented with additional copies of the cap gene. They not only generated rAAV with high titers upon induction but also achieved high full‐to‐empty particle ratios by tuning capsid formation through inducer concentrations and induction time profiles. Recombinant adeno‐associated virus (rAAV) is widely used as an in vivo delivery vector for gene therapy. It is used in a very large dose, and the large quantities required for broad applications present manufacturing challenges. We have developed a synthetic biology platform of constructing cell lines integrated with essential viral genes which can be induced to produce rAAV without plasmid transfection or virus transduction. Through iterative design‐construct‐characterization cycles, we have showcased the potential of this synthetic cell production system. Systems characterization of the dynamics of viral transcripts and proteins as well as virus assembly and packaging revealed that the expression level and balance of viral genome and capsid protein are keys to not only the productivity but also the full particle content, an important product quality attribute. Boosting cap gene expression by sequential transfection and integration of multiple copies of the cap gene elevated the rAAV titer to levels on a par with traditional plasmid transfection and virus infection. However, overexpression of the cap gene shifted the balance and kinetics of the genome and capsid. We independently tuned the dynamics of genome amplification and capsid protein synthesis by modulating the induction concentration as well as the time profile, and significantly enhanced full particle content while maintaining a high productivity. This strategy of constructing an inducible stable producer cell line is readily adaptable to rAAV vectors of different serotypes and payloads. It can greatly facilitate scalable production of gene therapy vectors.

Down-regulation of CD81 tetraspanin in human cells producing retroviral-based particles: tailoring vector composition

Design and selection of anti-PD-L1 single-domain antibody and tumor necrosis factor superfamily ligands for an optimal vectorization in an oncolytic virus

Effect of posttranscriptional regulatory elements on transgene expression and virus production in the context of retrovirus vectors

Retroviral hybrid LTR vector strategy: functional analysis of LTR elements and generation of endothelial cell specificity

Tuning capsid formation dynamics in recombinant adeno‐associated virus producing synthetic cell lines to enhance full particle productivity

Novel Combinatorial MicroRNA-Binding Sites in AAV Vectors Synergistically Diminish Antigen Presentation and Transgene Immunity for Efficient and Stable Transduction

Superior lentiviral vectors designed for BSL-0 environment abolish vector mobilization

Enhancement of rAAV titers via inhibition of the interferon signaling cascade in transfected HEK293 suspension cultures

Enhancing safety of cytomegalovirus-based vaccine vectors by engaging host intrinsic immunity

Scaleable purification process for gene therapy retroviral vectors

Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy

Suppression of toxic transgene expression by optimized artificial miRNAs increases AAV vector yields in HEK-293 cells

Development of a Bispecific Antibody-Based Platform for Retargeting of Capsid Modified AAV Vectors

Establishment of a novel stable human suspension packaging cell line producing ecotropic retroviral MLV(PVC-211) vectors efficiently transducing murine hematopoietic stem and progenitor cells

A robust platform for BaEVRless-lentiviral synthesis and primary natural killer cell transduction

Construction of a High Efficient Retrovirus Vector Psiv-1 and Its Preliminary Identification of Functions

An Shrna Silencing a Non‐toxic Transgene Reduces Nutrient Consumption and Increases Production of Adenoviral Vectors in a Novel Packaging Cell

Deciphering the impact of parameters influencing transgene expression kinetics after repeated cell transduction with integration-deficient retroviral vectors

Transgene expression knock-down in recombinant Modified Vaccinia virus Ankara vectors improves genetic stability and sustained transgene maintenance across multiple passages

Combined fiber modifications both to target α(v)β(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5

Precise Therapy Using the Selective Endogenous Encapsidation for Cellular Delivery Vector System